



Sheet 1 of 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50150/064001
		Serial No.	10/668,792
		Applicant	Bernard E. Cabana et al.
		Filing Date	September 23, 2003
		Group	1614
		IDS Filed	May 25, 2005
		Customer No.	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

U.S. PUBLISHED PATENT APPLICATION

Examiner's Initials	Publication Number	Publication Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
PS	20040176404	09/09/04	Sayada	514	252.13	
PS	20040126414	07/01/04	Michaelis	514	224.5	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

PS	"Rifalazil PathoGenesis Plans Phase II Studies," R&D Focus Drug News. June 9, 1997.

EXAMINER	<i>P. Spivack</i>	DATE CONSIDERED	<i>3/18/06</i>
-----------------	-------------------	------------------------	----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

Change(s) applied
to document,
/K.D.D./
11/1/2011